VMAT2 availability in Parkinson’s disease with probable REM sleep behaviour disorder

Table 1 Demographic, behavioural, clinical and PET imaging characteristics of participants

	HC	PD-RBD−	PD-RBD+	p value
N (M:F)	15 (3:12)	15 (8:7)	15 (10:5)	0.03^a
Age [years] ± SD (range)	67.1 ± 5.14 (58–79)	70.7 ± 5.67 (60–80)	68.1 ± 6.48 (56–80)	0.23
BDI ± SD	2.33 ± 1.29	3.00 ± 1.36	5.00 ± 4.32	0.03
MoCA ± SD	27.6 ± 2.13	24.93 ± 2.93	23.87 ± 3.24	0.002
Disease duration [years] ± SD	–	7.20 ± 4.49	6.76 ± 3.67	0.77
UPDRS-III ± SD	–	28.53 ± 17.18	23.87 ± 10.84	0.38
Hoehn and Yahr Score ± SD	–	2.20 ± 0.41	2.13 ± 0.39	0.68
LEDD [mg] ± SD	–	701.70 ± 522.04	723.45 ± 410.75	0.90
[¹¹C]DTBZ dose [mCi] ± SD	9.54 ± 0.87	9.33 ± 0.59	9.72 ± 0.45	0.29
[¹¹C]DTBZ mass [μg] ± SD	1.84 ± 1.78	1.28 ± 0.53	1.74 ± 1.31	0.48
[¹¹C]DTBZ specific activity [mCi/μmol] ± SD	2529.77 ± 1312.82	2658.75 ± 995.19	2319.78 ± 816.03	0.68

BDI, Beck Depression Inventory; HC, healthy controls; LEDD, levodopa equivalent daily dose (calculated according to Evans et al. [25]); MoCA, Montreal Cognitive Assessment; PD-RBD+, PD patients with probable RBD; PD-RBD−, PD patients without probable RBD; UPDRS-III, Unified Parkinson’s Disease Rating Scale III
^aPearson Chi-Square

ISSN: 1756-6606